Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

This study tests a combination of two types of drugs — one that boosts NMDA receptors in the brain (which affect learning and mood) and one that reduces inflammation — to treat schizophrenia and related psychotic disorders, aiming for better symptom control than current medications alone. **You may be eligible if...** - You have been diagnosed with schizophrenia or a related psychotic disorder - You are currently on antipsychotic medication but still experiencing symptoms - You are willing to try an add-on treatment combination **You may NOT be eligible if...** - You have severe medical conditions that make participation unsafe - You are pregnant or planning to become pregnant - You have a known allergy to the study medications *(Note: Full specific eligibility criteria were limited in available data.)* Talk to your doctor to see if this trial is right for you.